BC Innovations | Nov 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: October 2018

New Therapeutic Targets and Biomarkers: October 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during October. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Oct 18, 2018
Distillery Therapeutics


INDICATION: Asthma Rat studies suggest antagonizing TRPV1 or combined antagonism of its upstream activators LPAR1, LPAR2, LPAR3 and LPAR4 could help treat allergic asthma. In a rat model of allergic asthma, plasma levels of lysophosphatidic...
BC Innovations | Mar 5, 2015
Distillery Therapeutics

Therapeutics: Lysophosphatidic acid receptor 2 (LPAR2; EDG4; LPA2)

Gastrointestinal disease INDICATION: Gastrointestinal In vitro and mouse studies suggest that an LPAR2 agonist could help treat radiation-induced gastrointestinal syndrome. A chemical screen identified a sulfamoyl benzoic acid analog that agonized LPAR2 with EC50 ~100...
BioCentury | Jul 6, 2009
Product Development

Amira's lipid love affair

Spurred by academic research linking LPA1 to idiopathic pulmonary fibrosis, Amira Pharmaceuticals Inc. used its medicinal chemistry expertise in bioactive lipids to design antagonists for preclinical studies. The company presented proof-of-concept data in a mouse...
Items per page:
1 - 4 of 4